Cyto-Facto, a spin-out from the Cell Therapy Development Center (RDC) in Kobe, Japan, leads in GMP-compliant manufacturing and is Asia’s pioneer in CAR-T cell therapy production for Kymriah intravenous infusion. Building on a strong track record of successful technology transfers and operational excellence, Cyto-Facto now offers investigational product manufacturing using mesenchymal stem cells (MSC). With cutting-edge facilities and extensive expertise, Cyto-Facto is dedicated to advancing regenerative medicine and meeting the diverse needs of clients in the evolving cell therapy landscape.
選單